09.04.24 -- Demystifying AI Governance

Allogene Therapeutics' Dr. Zachary Roberts, penned an article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In it, he explains that CLL, the most common leukemia in the U.S., remains a disease that is managed but not often cured. Cell & Gene: The Podcast Host, Erin Harris, follows up with Roberts about his article, existing issues with CAR T approaches, "auto vs. allo," and why allogeneic is the path forward.

CNS Summit is more than a meeting. We are an exclusive, curated community of life sciences executives and innovators who are committed to year-round collaboration. We bring together top decision makers from pharma, biotech, and the whole life sciences ecosystem to Collaborate for Novel Solutions. Join us for our 15th anniversary at our 4-day annual event in Boston, November 10-13. Learn more here.

Adaptability is crucial for developers as they upscale the production of viral vectors. Explore the benefits of using suspension cell lines and why adherent cell culture shouldn’t be left behind.

Clinical trials can expose both predicted and unexpected safety signals. Understand why surveillance must therefore look beyond expected adverse events to detect possible safety signals.

Combining high-productivity chromatography methods and SU affinity membranes delivers a viable alternative to the current packed bed Protein A capture techniques for intensified purification of mAbs.

Increased demand for protein delivery and the emergence of advanced modalities – including mRNA – are introducing new challenges to the development lifecycle, such as high-concentration formulations.